Literature DB >> 27778124

Early detection of nonperitoneal recurrence may contribute to survival benefit after curative gastrectomy for gastric cancer.

Keiichi Fujiya1, Masanori Tokunaga1, Rie Makuuchi1, Noriyuki Nishiwaki1, Hayato Omori1, Wataru Takagi1, Fumiko Hirata1, Makoto Hikage1, Yutaka Tanizawa1, Etsuro Bando1, Taiichi Kawamura1, Masanori Terashima2.   

Abstract

BACKGROUND: There is no evidence that strict follow-up using cross-sectional imaging after curative gastrectomy benefits survival; however, nonperitoneal recurrence detected early might be treated with additional surgery. The present study examined whether early detection of recurrence by imaging modalities could increase survival, particularly in patients with nonperitoneal recurrence.
METHODS: We retrospectively analyzed 218 patients with recurrent gastric cancer after curative gastrectomy performed from 2002 to 2014. The patients were divided into an asymptomatic group (n = 117) and a symptomatic group (n = 101), according to the presence of symptoms at the time of recurrence, to compare clinicopathological characteristics and long-term survival.
RESULTS: Peritoneal recurrence was less frequent in the asymptomatic group (22.2%) than in the symptomatic group (62.4%), the median time to recurrence was shorter (12.7 months vs 18.9 months; P < 0.001), and the median survival time after recurrence was longer (18.7 months vs 7.5 months; P < 0.001). In the asymptomatic group, 10 of 117 patients (8.5%) received additional curative surgery after recurrence. Median overall survival after gastrectomy was not significantly different between the groups (30.1 months for the asymptomatic group vs 30.0 months for the symptomatic group; P = 0.132); however, it was significantly longer among asymptomatic patients with nonperitoneal recurrence compared with symptomatic patients (35.9 months vs 24.0 months; P = 0.039).
CONCLUSIONS: The presence of symptoms at recurrence did not affect survival in patients with recurrent gastric cancer. However, detection of nonperitoneal recurrence before the appearance of symptoms may provide survival benefit. Therefore, regular follow-up, including use of imaging modalities, is recommended.

Entities:  

Keywords:  Chemotherapy; Computed tomography; Follow-up; Hematogenous recurrence; Hepatectomy

Mesh:

Year:  2016        PMID: 27778124     DOI: 10.1007/s10120-016-0661-x

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  23 in total

1.  Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit.

Authors:  Yasuhiro Kodera; Seiji Ito; Yoshitaka Yamamura; Yoshinari Mochizuki; Michitaka Fujiwara; Kenji Hibi; Katsuki Ito; Seiji Akiyama; Akimasa Nakao
Journal:  Ann Surg Oncol       Date:  2003-10       Impact factor: 5.344

2.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

3.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

4.  Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer.

Authors:  Yoshihiro Sakamoto; Takeshi Sano; Kazuaki Shimada; Minoru Esaki; Makoto Saka; Takeo Fukagawa; Hitoshi Katai; Tomoo Kosuge; Mitsuru Sasako
Journal:  J Surg Oncol       Date:  2007-06-01       Impact factor: 3.454

5.  Staging Laparoscopy for Patients with cM0, Type 4, and Large Type 3 Gastric Cancer.

Authors:  Yuichiro Miki; Masanori Tokunaga; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masanori Terashima
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

Review 6.  Follow-up of gastric cancer: a review.

Authors:  John Whiting; Takeshi Sano; Makoto Saka; Takeo Fukagawa; Hitoshi Katai; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

7.  The prognostic value of detecting symptomatic or asymptomatic recurrence in patients with gastric cancer after a curative gastrectomy.

Authors:  Ahmet Bilici; Tarik Salman; Bala Basak Oven Ustaalioglu; Tugba Unek; Mesut Seker; Mehmet Aliustaoglu; Cem Gezen; Tarkan Unek; Dilek Yavuzer; Mehtat Unlu; Mahmut Gumus; Ugur Yilmaz
Journal:  J Surg Res       Date:  2012-04-11       Impact factor: 2.192

Review 8.  Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of ¹⁸F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature.

Authors:  Hideaki Shimada; Shinichi Okazumi; Masamichi Koyama; Koji Murakami
Journal:  Gastric Cancer       Date:  2011-02-18       Impact factor: 7.370

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Authors:  Atsushi Ohtsu; Yasuhiro Shimada; Kuniaki Shirao; Narikazu Boku; Ichinosuke Hyodo; Hiroshi Saito; Noboru Yamamichi; Yoshinori Miyata; Nobumasa Ikeda; Seiichiro Yamamoto; Haruhiko Fukuda; Shigeaki Yoshida
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

View more
  8 in total

1.  Score of the preoperative absolute number of lymphocytes, monocytes, and neutrophils as a prognostic indicator for patients with gastric cancer.

Authors:  Hiroaki Saito; Shota Shimizu; Yusuke Kono; Yuki Murakami; Yuji Shishido; Kozo Miyatani; Tomoyuki Matsunaga; Yoji Fukumoto; Keigo Ashida; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2019-05-06       Impact factor: 2.549

2.  Postoperative ratio of the maximum C-reactive protein level to the minimum peripheral lymphocyte count as a prognostic indicator for gastric cancer patients.

Authors:  Yusuke Kono; Hiroaki Saito; Yuki Murakami; Yuji Shishido; Hirohiko Kuroda; Tomoyuki Matsunaga; Manabu Yamamoto; Yoji Fukumoto; Tomohiro Osaki; Keigo Ashida; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2018-10-13       Impact factor: 2.549

3.  Symptomatic Recurrence and Survival Outcomes After Curative Treatment of Gastric Cancer: Does Intensive Follow-up Evaluation Improve Survival?

Authors:  Thiago Pereira Diniz; Wilson L da Costa; Camila Couto Gomes; Victor Hugo F de Jesus; Tiago C Felismino; Silvio Melo Torres; Héber S C Ribeiro; Alessandro L Diniz; André Luís de Godoy; Igor Correia de Farias; Emmanuel Dias-Neto; Maria Paula Curado; Felipe J F Coimbra
Journal:  Ann Surg Oncol       Date:  2021-11-15       Impact factor: 5.344

4.  Duration of Postoperative Fever as a Simple and Useful Prognostic Indicator in Gastric Cancer Patients.

Authors:  Hirohiko Kuroda; Hiroaki Saito; Yuki Murakami; Yuji Shishido; Kozo Miyatani; Tomoyuki Matsunaga; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2021-08-06       Impact factor: 1.641

Review 5.  Comparison of CEA and CA19-9 as a predictive factor for recurrence after curative gastrectomy in gastric cancer.

Authors:  Chikashi Shibata; Toru Nakano; Akihiro Yasumoto; Atsushi Mitamura; Kentaro Sawada; Hitoshi Ogawa; Tomoya Miura; Ichiro Ise; Kazuhiro Takami; Kuniharu Yamamoto; Yu Katayose
Journal:  BMC Surg       Date:  2022-06-03       Impact factor: 2.030

6.  Follow-up after curative resection for gastric cancer: Is it time to tailor it?

Authors:  Paolo Aurello; Niccolò Petrucciani; Laura Antolino; Diego Giulitti; Francesco D'Angelo; Giovanni Ramacciato
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

7.  Prognostic Value of Restaging F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict 3-Year Post-Recurrence Survival in Patients with Recurrent Gastric Cancer after Curative Resection.

Authors:  Sung Hoon Kim; Bong Il Song; Hae Won Kim; Kyoung Sook Won; Young Gil Son; Seung Wan Ryu
Journal:  Korean J Radiol       Date:  2020-07       Impact factor: 3.500

8.  Blood parameters score predicts long-term outcomes in stage II-III gastric cancer patients.

Authors:  Jian-Xian Lin; Yi-Hui Tang; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Chang-Ming Huang; Ping Li; Chao-Hui Zheng; Jian-Wei Xie
Journal:  World J Gastroenterol       Date:  2019-11-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.